Sarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.
Sarah Weiss, MD
Advertisement
Articles by Sarah Weiss, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS
5